The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter

被引：0
|
作者：
Leon, Leticia G. [1 ,2 ]
Funel, Niccola [1 ]
Peters, Godefridus J. [3 ]
Avan, Amir [4 ,5 ]
Vistoli, Fabio [6 ]
Boggi, Ugo [6 ]
Giovannetti, Elisa [1 ,3 ]
机构：
[1] Univ Pisa, Canc Pharmacol Lab, AIRC Start UP Unit, I-56124 Pisa, Italy
[2] Univ La Laguna, Ctr Biomed Res Canary Isl, Inst Tecnol Biomed, E-38207 San Cristobal la Laguna, Spain
[3] VU Univ Med Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands
[4] Mashhad Univ Med Sci, Dept Modern Sci & Technol, Sch Med, Mashhad, Iran
[5] Mashhad Univ Med Sci, Canc Res Ctr, Sch Med, Mashhad, Iran
[6] Univ Pisa, Div Gen & Transplant Surg, I-56124 Pisa, Italy
来源：
CLINICAL CANCER RESEARCH | 2016年 / 22卷 / 10期
关键词：
PANCREATIC-CANCER; ANTITUMOR-ACTIVITY;
D O I：
10.1158/1078-0432.CCR-16-0259
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2594 / 2594
页数：1
相关论文
共 50 条
  • [21] Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas
    Inaba, Kanako
    Oda, Katsutoshi
    Ikeda, Yuji
    Sone, Kenbun
    Miyasaka, Aid
    Kashiyama, Tomoko
    Fukuda, Tomohiko
    Uehara, Yuriko
    Arimoto, Takahide
    Kuramoto, Hiroyuki
    Wada-Hiraike, Osamu
    Kawana, Kei
    Yano, Tetsu
    Osuga, Yutaka
    Fujii, Tomoyuki
    GYNECOLOGIC ONCOLOGY, 2015, 138 (02) : 323 - 331
  • [22] Preclinical study of MEK1/2 inhibitor AZD6244 combined with gemcitabine for treatment of biliary cancer.
    Xu, Junyao
    Knox, Jennifer J.
    Tsao, Ming Sound
    Chen, Eric Xueyu
    Cao, Pinjiang
    Sue, Chow
    Serra, Stefano
    Hedley, David W.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [23] AZD-6244.: MEK1/2 inhibitor, oncolytic.
    Revill, P.
    Serradell, N.
    Bolos, J.
    Bozzo, J.
    DRUGS OF THE FUTURE, 2006, 31 (10) : 854 - 858
  • [24] The Use of a Chemical Biology in the Development of a Novel MEK1/2 Inhibitor
    Yoshida, Takayuki
    Yamaguchi, Takayuki
    Kawasaki, Hisashi
    Sakamoto, Shinji
    JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 2016, 74 (05) : 462 - 468
  • [25] Macrocyclic MEK1/2 inhibitor with efficacy in a mouse model of cardiomyopathy caused by lamin A/C gene mutation
    Wu, Wei
    Chordia, Mahendra D.
    Hart, Barry P.
    Kumarasinghe, E. Sathyajith
    Ji, Min K.
    Bhargava, Ajay
    Lawlor, Michael W.
    Shin, Ji-Yeon
    Sera, Fusako
    Homma, Shunichi
    Muchir, Antoine
    Khire, Uday R.
    Worman, Howard J.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (03) : 1004 - 1013
  • [26] The histone deacetylase inhibitor entinostat enhances the efficacy of the MEK inhibitor pimasertib against aggressive types of breast cancer through Noxa-mediated myeloid cell leukemia 1 degradation
    Torres-Adorno, A. M.
    Lee, J. J.
    Kogawa, T.
    Bartholomeusz, C.
    Pitner, M. K.
    Ordentlich, P.
    Lim, B.
    Tripathy, D.
    Ueno, N. T.
    CANCER RESEARCH, 2016, 76
  • [27] Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2
    Yoshida, Takayuki
    Kakegawa, Junya
    Yamaguchi, Takayuki
    Hantani, Yoshiji
    Okajima, Nobuyuki
    Sakai, Toshiyuki
    Watanabe, Yoshihiro
    Nakamura, Motonao
    ONCOTARGET, 2012, 3 (12) : 1533 - 1545
  • [28] Characterization of GSK1120212 a novel allosteric inhibitor of MEK1/2
    Erskine, S.
    Rominger, C.
    Zappacosta, F.
    Laquerre, S.
    Adams, J.
    Tummino, P.
    Lai, Z.
    EJC SUPPLEMENTS, 2008, 6 (12): : 44 - 45
  • [29] Cisplatin inhibits MEK1/2
    Yamamoto, Tetsu
    Tsigelny, Igor F.
    Goetz, Andreas W.
    Howell, Stephen B.
    ONCOTARGET, 2015, 6 (27) : 23510 - 23522
  • [30] Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors
    Mita, Monica
    Fu, Siqing
    Piha-Paul, Sarina Anne
    Janku, Filip
    Mita, Alain
    Natale, Ronald
    Guo, Wei
    Zhao, Charles
    Kurzrock, Razelle
    Naing, Aung
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 616 - 626
12345